Groups
Company Size (Fulltime employees)
Looking for
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

D2M Biotherapeutics United States

A human-genetics driven next generation immunity-oncology company
Website:
www.d2mbio.com
Looking for
Headquartner in China
No
Nan Bing
CEO 
Functionality
Management

Daiichi Sankyo Japan

Weiyong Sun
Senior Director 

Dawn Biopharmaceuticals Inc. United States

Dawn Biopharmaceuticals Inc (DBI) is a US firm founded by Gordon Lee, MD (UK MBChB), MBA (Wharton) who has access to a proprietary cell-based immunotherapeutic product for clinical development in the US. The product is a multivalent cancer therapy that integrates multiple anti-cancer mechanisms in one modifiable platform. The product is tumor-homing, disables the local tumor defenses and expresses a therapeutic cytokine in the cancer - but not systemically.

(Please note that the website is pending.)

Website:
dawnbio.net
Company Size (Fulltime employees)
1-10
Year of foundation
2020
Looking for
Please specify your partnering goal
Strategic pharmaceutical or capital partner to accompany into Pre-IND and clinical trials.
Funding Status
Initial round
Headquartner in China
No
Plan in China
Open to partnerships with Chinese firms that have a proprietary small molecule or biodrug that could be encoded into our platform with the benefits of wider scope of applications, tumor-centric molecular therapeutic delivery, avoidance of peripheral (extra tumoral) actions and effects, and vectoring of high payload(s) for multi-arming.
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Gordon Lee
Founder 
Functionality
Management

Deutsche Bank AG London United Kingdom

Deutsche Bank is the largest bank in Germany and one of only 4 Depositary Receipt banks able to list Life Sciences and Medtech companies on US exchanges using ADRs.
Website:
www.dbadr.com
Company Size (Fulltime employees)
5000+
Year of foundation
1886
Looking for
Please specify your partnering goal
Meet companies hoping to list and raise capital in the US
Headquartner in China
No
Joseph Oakenfold
Vice President 
Functionality
Business Development

DIMITAR DIMITROV Bulgaria

Micar Innovation is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through discovery novel blockbuster drug molecules for a large class of diseases (Pipeline). Micar Innovation focuses on entire drug discovery process using improved structure based insilico drug design from scratch till Preclinical phase with advanced predictions of activity, selectivity and ADMET

Website:
http://micar21.com/
Company Size (Fulltime employees)
1-10
Year of foundation
2016
Looking for
Please specify your partnering goal
Drug Discovery
Funding Status
raising
Now raising (In USD)
2500000
Headquartner in China
No
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Investment Focus
Oncology project
Slides Deck
(pdf, 939.67KB)
CEO 
Functionality
Management

DivaOra Group Russia

Manufacturing, whole sale innovation product EYEIMPROVER.com - the stimulator for the eyes
Website:
www.eyeimrpver.com
Company Size (Fulltime employees)
1-10
Year of foundation
2016
Looking for
Funding Status
investment, strategy investor
Headquartner in China
No
Plan in China
We want move our business from CHINA. We searshin investment and we are ready for relocation.
Olga Oshurkova
CEO & Owner 
Functionality
Management

Drive Therapeutics, LLC United States

Drive Therapeutics is developing a novel, long acting, bispecific nucleic acid therapeutic to block the angiogenesis, inflammation, and fibrosis underlying retinal disease. Drive’s lead program is a bispecific aptamer therapeutic made up of two well validated components: a pan-specific anti-VEGF-A aptamer and an anti-Interleukin-8 (IL8) aptamer. Drive’s lead program will mitigate poor patient response to existing anti-VEGF therapy, improve outcomes and reduce patient burden. By targeting both angiogenesis and a critical immune pathway that drives both inflammation and angiogenesis, Drive’s bispecific inhibitor is the key to overcoming the limitations of VEGF monotherapy. In addition to current candidates, Drive’s aptamer therapeutic discovery platform will allow for streamlined, efficient development of new therapies to pathologically relevant ophthalmologic targets.
Website:
drivetherapeutics.com
Company Size (Fulltime employees)
1-10
Year of foundation
2019
Looking for
Please specify your partnering goal
Looking for a partner to move the program forward to get proof of concept
Funding Status
Seed Stage
Now raising (In USD)
600k- 2.0 MM
Headquartner in China
No
Plan in China
We feel that our product would be very successful in the China market. A co-development deal would be ideal.
Biotech/Pharma Category
Ryan Quick
Co-founder and COO 
Functionality
Management